Ratings for Conmed (NYSE:CNMD) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $87.83, along with a high estimate of $106.00 and a low estimate of $71.00. A decline of 7.55% from the prior average price target is evident in the current average.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of Conmed by financial experts is...